Tislelizumab and huaier granule for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs: tislelizumab (an immunotherapy that helps your immune system attack cancer) and huaier granule (a traditional Chinese medicine extract). It is for people with advanced liver cancer that cannot be removed by surgery and who have not had other systemic treatments before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have a confirmed diagnosis of hepatocellular carcinoma (a type of liver cancer)
- Your cancer is at a stage where it cannot be surgically removed or has worsened after local treatments like chemoembolization
- You have not had any systemic (whole-body) cancer treatment for your liver cancer before
- You have at least one measurable tumor that has not been treated locally or has grown after local treatment
- Your liver function is relatively good (Child-Pugh class A)
- You are generally up and about (ECOG performance status 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of liver-directed chemotherapy, targeted therapy, and immunotherapy to shrink advanced liver cancer that has a blood clot in the portal vein (the main vein to the liver). The goal is to make the tumor removable by surgery.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests whether combining two targeted drugs (lenvatinib and tislelizumab) works better than lenvatinib alone for people with advanced liver cancer whose disease worsened after prior treatment with an immunotherapy and a blood vessel growth blocker (bevacizumab).
This trial tests combining three drugs (atezolizumab, bevacizumab, and tocilizumab) to see if they can help people with advanced liver cancer that cannot be removed with surgery. It aims to shrink tumors and improve outcomes for patients who have not had prior systemic therapy.
This trial tests a new combination of two drugs (WGc-0201 plus Tislelizumab) to help prevent liver cancer from coming back after you've had surgery or ablation. It is for people with hepatitis B who are at high risk for recurrence.
This study tests a combination of three drugs—TUDCA (a bile acid supplement), camrelizumab (an immunotherapy), and regorafenib (a targeted therapy)—for people with advanced liver cancer that has continued to grow after earlier immunotherapy plus Avastin treatment. The goal is to see if this new mix can help stop the cancer from growing.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.